Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + methotrexate + temozolomide + thiotepa
- Development stage
- Unknown
- Lead developer
- IDEC
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of rituximab (anti-CD20 monoclonal antibody), high-dose methotrexate (antimetabolite), temozolomide (alkylating agent), and thiotepa (alkylating agent). This regimen is primarily used in the treatment of primary central nervous system lymphoma (PCNSL) and other malignant brain tumors. The combination has shown promising response rates and improved progression-free survival compared to regimens without rituximab.
- Other names
- MRTRMT
02
Targets
Beyond the preview
Go deeper on rituximab + methotrexate + temozolomide + thiotepa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + methotrexate + temozolomide + thiotepa.